Toggle light / dark theme

Hype aside demonstration that epigentic reprogramming can reverse some of the aging process is an important step forward for progress. We can expect to see this moving to human trials in the next decade or so making the future an exciting possibility.


Science is increasingly coming to the conclussion that aging is amenable to intervention and that it is a plastic process that we can manipulate. More research in this week shows that aging is indeed elastic and is not a one way process at all. The sooner society accepts what the data from the labs is showing the sooner we can cure age-related diseases for healthier longer lives!

“We did not correct the mutation that causes premature aging in these mice,” lead researcher Juan Carlos Izpisua Belmonte said in a recent statement. “We altered aging by changing the epigenome, suggesting that aging is a plastic process.”

Read more

More progress on the cancer front! Controlling cancer effectively is a critical part of rejuvenation biotechnology and therefore all cancer progress is of great interest to our community. If there was a poster child of aging diseases, cancer would be at the front of the queue.

“The results could lead to new treatments—not only for a variety of cancers, but also other diseases that arise from faulty proteinases, such as Alzheimer’s, asthma, multiple sclerosis and arthritis.”

Read more

Biologist Daisy Robinton talks about engineering aging and the possibilities new technology offers.


Harvard University biologist Daisy Robinton reveals how science is helping us understand how and why we age.

Daisy Robinton is a scientist at Harvard University researching mechanisms of stem cell identity at the intersection of cancer and developmental biology. Daisy’s passion for the effective translation of science has fuelled her years of teaching and speaking, and in 2011 Daisy founded the Science in the News Spring Public Lecture Series at Harvard. Daisy consults to numerous biotech startups in the US and UK and for projects ranging from feature film screenplays on the future of medicine and longevity to the “Future of Making” via bioengineering with IDEO.

This talk was given at a TEDx event using the TED conference format but independently organized by a local community.

Read more

A ‘living bandage’ made from stem cells, which could revolutionise the treatment and prognosis of a common sporting knee injury, has been trialled in humans for the first time by scientists at the Universities of Liverpool and Bristol.

Meniscal tears are suffered by over one million people a year in the US and Europe alone and are particularly common in contact sports like football and rugby. 90% or more of tears occur in the white zone of meniscus which lacks a blood supply, making them difficult to repair. Many professional sports players opt to have the torn tissue removed altogether, risking osteoarthritis in later life.

The Cell Bandage has been developed by spin-out company Azellon, and is designed to enable the meniscal tear to repair itself by encouraging cell growth in the affected tissue.

Read more

Check out the LEAF interview with Synthetic Biology company CellAge who plan to use their technology to create aging biomarkers for the research community to use for free as well as new approaches to removing senescent cells.


CellAge are using synthetic biology to remove senescent cells that accumulate with age and contribute to disease. We took the time to interview them about their technology, treating age-related diseases and their plans for the future.

You can also check out their campaign on Lifespan.io:

https://www.lifespan.io/campaigns/cellage-targeting-senescent-cells-with-synthetic-biology/

Read more

Progress with treating osteoporosis.


A team of scientists at the Children’s Medical Center Research Institute at UT Southwestern (CRI) discovered a new bone-forming growth factor, Osteolectin (Clec11a), which reverses osteoporosis in mice and has implications for regenerative medicine.

Although Osteolectin is known to be made by certain marrow and , CRI researchers are the first to show Osteolectin promotes the formation of new bone from skeletal stem cells in the bone marrow. The study, published in eLife, also found that deletion of Osteolectin in mice causes accelerated bone loss during adulthood and symptoms of , such as reduced bone strength and delayed fracture healing.

“These results demonstrate the important role Osteolectin plays in new bone formation and maintaining adult bone mass. This study opens up the possibility of using this growth factor to treat diseases like osteoporosis,” said Dr. Sean Morrison, who led the team that made the discovery. Dr. Morrison, CRI Director, holds the Mary McDermott Cook Chair in Pediatric Genetics at UT Southwestern Medical Center, and the Kathryne and Gene Bishop Distinguished Chair in Pediatric Research at Children’s Research Institute at UT Southwestern.

Read more

Dr. Aubrey de Grey on the case again in this amusing video.


Dr. Aubrey de Grey in a new video where people ask questions via Twitter. It is a bit tongue in cheek and sorry about the title but hopefully you will enjoy it,

If you liked this video and agree that eliminating age-related diseases is a good idea please consider visiting our website and making a donation for science on the link below:

http://www.sens.org/donate

Read more